Page 7 - Life Sciences Practice News Today

Lobbyists expected the current pace of business to continue at least through the end of the year, if not well into 2022.

Jon an experienced attorney is also Chair of the Securities & Capital Markets Practice Group and Co-chair of the Life Sciences Practice Group at Mintz Levin. He represents clients in both public and privately placed equity and debt financings under the Securities Act of 1933, provides counseling for public companies with respect to the full range of securities compliance issues

/PRNewswire/ -- Today, Pacific Program Management (PPM) announced the launch of a dedicated Life Sciences Practice. With headquarters in Seattle and operations...

/PRNewswire/ -- Today, Pacific Program Management (PPM) announced the launch of a dedicated Life Sciences Practice. With headquarters in Seattle and operations...

Skills and talent development company NIIT Limited on Friday announced the expansion of its board with four new members, including promoters children Udai S Pawar and Leher V Thadani. The move marks succession planning by promoters with their children - Udai S Pawar and Leher V Thadani - on the board, even as they emphasised that the two new faces are not joining in a management capacity. The company said the expansion of the board, including elevation of CEO Sapnesh Lalla to the board, is a...

Relief Announces Notice of Annual General Meeting of RELIEF THERAPEUTICS Holding AG EQS Group-News: RELIEF THERAPEUTICS Holdings AG / Key word(s): AGMEGM 27.05.2021 / 07:00 Geneva, Switzerland, May 27, 2021 - RELIEF THERAPEUTICS Holding AG (SIX: RLF, OTCQB: RLFTF) (" Relief" or the " Company"), a biopharmaceutical company with its lead compound RLF-100 TM (aviptadil) in advanced clinical development to treat severe COVID-19 patients, today gives notice of the Annual General Meeting (AGM) of ...

GENEVA, SWITZERLAND / ACCESSWIRE / May 27, 2021 / RELIEF THERAPEUTICS Holding AG (SIX: RLF, OTCQB: RLFTF) ("Relief" or the "Company"), a biopharmaceutical company with its lead compound RLF-100TM (aviptadil)

Curative cell and gene therapies and healthcare system disruption SHARES Introduction Significant scientific advances have created a rich clinical research pipeline, with innovative and potentially curative cell and gene therapies already available (eg, Kymriah ® for acute lymphoblastic leukaemia, Luxturna ® for inherited retinal disease and Zolgensma ® for spinal muscular atrophy). Over the next 10 years, more of these therapies are expected to enter the market for other disease areas and l...

Harnessing The Power Of AI In MS Diagnosis, Monitoring, And Treatment By Andrew Thomson, Logan Wright, and Lev Gerlovin, Life Sciences Practice, CRA Applications of artificial intelligence (AI) are rapidly expanding in healthcare, including the handling of administrative logistics at hospitals, assessment of patient health data, and analysis of novel molecules in drug discovery. A prime example of the future potential of AI is in revolutionizing the way we diagnose, monitor, and treat multiple ...

Overcoming Funding Challenges For Innovative Medtech In Germany: Learnings From The NUB Process By Eva Marchese, Lorenzo D’Angelo, Anthony Barron, and Oriol Viader-Llargués, CRA Germany is the leading medtech market in Europe, with a 22% market share. While funding for high-cost innovative medtech in Germany has evolved in recent years, there are still many challenges in securing reimbursement even as demand for these technologies surges. In a new analysis conducted by our Life Sciences Prac...